REIG JOFRE publishes its Q1 2026 financial results
REIG JOFRE ADVANCES ITS GROWTH SUPPORTED BY ITS INDUSTRIAL AND BIOTECH EXPANSION
Q1 2026 key figures
- Revenue: €86 million (–2% vs. Q1 2025), impacted by a temporary disruption in Forté Pharma’s supply chain in France and Belgium.
- Gross margin: 60%, in line with the previous year.
- Consolidated EBITDA: €10 million (+1% vs. Q1 2025), driven by growth in Specialty Pharmacare.
- Consolidated net profit: €3 million, €0.6 million below Q1 2025, due to higher financial expenses and asset impairment expected to be recovered over the course of the year.
- Net financial debt: €102 million; NFD/EBITDA ratio of 3.3x, stable compared with year-end 2025.
- Operating milestones: progress on new production lines, the launch of injectable dalbavancin, and continued progress in the biotechnology integration of Leanbio and Syna Therapeutics.
REIG JOFRE, (BME:RJF), closed the first quarter of 2026 consolidating its profitability improvement and advancing on its key strategic priorities. EBITDA reached €10 million, up 1% compared with the same period of the previous year, driven by the osteoarticular and dermatology areas.
At the same time, the company continued to execute its roadmap across two distinct areas. On the one hand, it advanced in technological innovation and industrial capabilities, with significant progress in Toledo and Barcelona, as well as in the integration of Leanbio and Syna Therapeutics, strengthening its biotechnology platforms. On the other hand, it reinforced its hospital portfolio and its presence in the anti-infectives therapeutic area with the launch of dalbavancin.
Against this backdrop, revenue amounted to €86 million, down 2% compared with the same period of the previous year, affected by a one-off supply chain disruption at Forté Pharma in France and Belgium, due to a fire in the second half of March. This impact, covered by the company’s insurance policy, is temporary in nature and the affected sales are expected to be transferred to the coming quarters of the year.
Commissioning of new production capacities
During the first quarter of 2026, REIG JOFRE continued to advance its industrial and technological investment programme, focused on strengthening differentiated capabilities in higher value-added areas, including advanced CDMO services.
From an industrial perspective, the company is progressing as planned in the commissioning of new production lines, with a focus on the new antibiotics manufacturing line in Toledo, the development of the Sterile Area in Barcelona and the construction of Leanbio’s GMP plant. These initiatives will enable the company to increase capacity, improve productivity and strengthen supply reliability in essential healthcare areas, with full capacity expected in the second half of 2026.
Fixed assets amounted to €203 million at the end of the quarter, compared with €199 million at year-end 2025. The evolution includes €2.8 million of industrial investments, €5.7 million in R&D projects, €0.5 million in digital projects and €1.7 million in right-of-use assets, partially offset by €6.5 million of depreciation and amortisation.